Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

Experimental Hematology & Oncology
P B JohnstonRadhakrishnan Ramchandren

Abstract

The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to respond, additional high-dose chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) can improve progression-free survival (PFS). Novel therapies are required for patients refractory to chemotherapy and AHSCT. The mammalian target of rapamycin inhibitor everolimus has shown preliminary activity in preclinical models of HL and promising efficacy in patients with relapsed or refractory HL. This was an open-label, two-stage, phase 2 study that enrolled 57 patients aged ≥ 18 years with classic HL that had progressed after standard therapy. Patients received everolimus 10 mg daily until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision. The primary endpoint was overall response rate; secondary endpoints included PFS, overall survival, time to response, duration of response, and safety. Overall response rate was 45.6% (95% confidence interval [CI] 32.4-59.3%); five patients (8.8%) experienced a complete response and 21 patients had a partial response (36.8%). Median PFS was 8.0 months (95% CI 5.1-11.0 months). Seven pati...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Sep 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen W L YeeFrancis J Giles
Oct 3, 2007·Hematology/oncology Clinics of North America·Bruce D Cheson
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Irene M GhobrialThomas E Witzig
Nov 5, 2010·The New England Journal of Medicine·Anas YounesAndres Forero-Torres
Jan 26, 2011·Blood·John KuruvillaMichael Crump
Apr 13, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Camillo PortaRobert J Motzer
Oct 20, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D A EichenauerUNKNOWN ESMO Guidelines Working Group
Mar 6, 2012·The Oncologist·Radhakrishnan Ramchandren
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Apr 6, 2012·The Korean Journal of Hematology·Erin-Siobhain R Currin, Ajay K Gopal
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesAndreas Engert
Apr 2, 2014·Transplantation Reviews·Bruce KaplanJason R Wellen
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Jan 27, 2017·Journal of Hematology & Oncology·Jun WangZihai Li
Dec 3, 2017·Journal of Hematology & Oncology·Bingshan LiuDelong Liu

❮ Previous
Next ❯

Citations

Nov 9, 2018·British Journal of Haematology·Boris Böll, Helen Görgen
Dec 12, 2018·British Journal of Haematology·Gottfried von Keudell, Anas Younes
Apr 11, 2018·American Journal of Hematology·Stephen M Ansell
Aug 4, 2018·Der Nervenarzt·S KnaussM Endres
May 2, 2020·Cells·Burkitkan AkbaySvetlana Dokudovskaya
Jul 7, 2019·Journal of Hematology & Oncology·Hui HuaYangfu Jiang
Jun 20, 2019·Frontiers in Oncology·Stefania CrisciAntonio Pinto
Feb 8, 2019·British Journal of Haematology·Monika L Metzger, Christine Mauz-Körholz
Aug 12, 2018·International Journal of Molecular Sciences·Hannah E Walters, Lynne S Cox
Apr 3, 2019·Cancers·Alain Antoine MinaBarbara Pro
Feb 29, 2020·Therapeutic Advances in Hematology·Theodoros P VassilakopoulosMaria K Angelopoulou
Dec 7, 2019·Hematology·Reid W Merryman, Ann LaCasce
Jan 26, 2021·Frontiers in Oncology·Yimei FengXi Zhang
Oct 16, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Filip JankuMichelle A Fanale
Jan 18, 2022·Leukemia & Lymphoma·Karan Chohan, Stephen M Ansell

❮ Previous
Next ❯

Methods Mentioned

BETA
ICE

Clinical Trials Mentioned

NCT01022996
NCT01075321
NCT01453504
NCT01665768
NCT02254239

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

© 2022 Meta ULC. All rights reserved